

## PROVINCIAL FUNDING SUMMARY

### Regorafenib (Stivarga) for Metastatic Colorectal Cancer

pERC Recommendation: Does Not Recommend  
For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: December 2, 2013

This information is current as of November 24, 2014. The use of this document is directed by [pCODR's Terms of Use](#).

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Not funded		
AB	Not funded		
SK	Not funded		
MB	Under provincial consideration*		
ON	Under provincial consideration*		
NS	Under provincial consideration*		
NB	Not funded		
NL	Not funded		
PEI	Not funded		

\**Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pricing Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.